2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/JtaBxVjoak https://t.co/k34P6SjC6L

Proposed modified SRI (SLE Responder Index) - Reduction in SLEDAI-2K ≥4 (w/ no worsening in MD global (PGA) ≥0.3). mSRI responders had signif lower Dz activity & pred dose, More LLDAS & remission, less damage accrual (p<0.001) https://t.co/lwsZpnRz3l https://t.co/V7pDYswM7b

Five Senses of Medicine - nice graphic download on Clinical Skils (from Annals of Internal Medicine) https://t.co/zeA0bK2Xpe https://t.co/vCasZmRaOY

Interesting read on "The art of paying attention" Narrative medicine: "attention, representation, and affiliation" “noticing the words we usually ignore” “taking the temperature of the conversation.” “meta-questions”, like “How are we doing so far? https://t.co/Pvx2GOQTgd https://t.co/wswf7Enaie

Be wary when you seen new drugs described as “cutting edge,” “game changing,” and “ground breaking” - as this is more likely advertising than reality. https://t.co/oB9xDFqCg6 https://t.co/wfVyR0P4bS

RCT of allopurinol in 183 #gout pts. After 6.5 yrs 30% (60) were dead. Survivors 82% Rx w allopurinol, 4% febuxostat, 8% not on ULT. Urate levels only available in 72%!! & only 58% achieved SU T2T <6 mg/dl (<0.36 mmol/L) Dont you think we should do better? https://t.co/NwS6I2A9M8 https://t.co/xvarJQJG2N

Joint Flares extend disease & show joint specific memory. Study of 95 JIA pts, 12.5 yrs F/U: 95% got to inactive dz, 81% flared 1+ times. 74% flares in prior joints, usual side 83%, contralateral 17%, 40% new Jt; more likely off meds https://t.co/20UEtZXUIW https://t.co/yDt7WXvkB0

Uncommon Misdiagnosis of Rheumatoid Arthritis Using long-term patient data from the BARFOT study of early RA patients, researchers at the Karolinska Institute have shown that use of the ACR-1987 classification criteria was highly precise. https://t.co/aHI0KW35Q2 https://t.co/Nk0vRNGYBI

#Gout Guidelines--> great outcomes! French study of 300 pts; 95% followed French Rx Guidelines, T2T SU < 6 mg/dL in 59% @6mos, 79% @24 mos & @2 yrs hald were Rx w/ allopurinol (313 mg/d) and 48% febuxostat (84 mg/d) https://t.co/iQ9NvHJXd8 https://t.co/2tkBWrHY32

"Double blind" an interesting read (Ann Int Med) of early COVID w/ no known effective therapy, doctor trepidation & and the bravery/will of sick ICU COVID pts as they consent to to enroll in the blinded ACTT trial w/ remdesivir https://t.co/N2bZq0JDmn https://t.co/iPLnNtQoER

Study of 67 OA TKR pts looked for CPPD - defined as "appears as linear/punctate opacities w/in cartilage, synovium, Jt capsule or tendons/entheses". Xrays had specificity of 92%, sensitivity 54%, PPV 88%, NPV 66% (needs to be distinguished from BCP) https://t.co/Nd9FZKyOHy https://t.co/m9PYofGE04